Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,940 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.
Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Kawahara T, Ohashi Y, Mukai H; RESPECT study group. Sawaki M, et al. Among authors: baba s. J Clin Oncol. 2020 Nov 10;38(32):3743-3752. doi: 10.1200/JCO.20.00184. Epub 2020 Sep 16. J Clin Oncol. 2020. PMID: 32936713 Clinical Trial.
Prevalence and differentiation of hereditary breast and ovarian cancers in Japan.
Nakamura S, Takahashi M, Tozaki M, Nakayama T, Nomizu T, Miki Y, Murakami Y, Aoki D, Iwase T, Nishimura S, Yamauchi H, Ohsumi S, Baba S, Shimizu T. Nakamura S, et al. Among authors: baba s. Breast Cancer. 2015 Sep;22(5):462-8. doi: 10.1007/s12282-013-0503-1. Epub 2013 Nov 19. Breast Cancer. 2015. PMID: 24249303
Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
Hida AI, Sagara Y, Yotsumoto D, Kanemitsu S, Kawano J, Baba S, Rai Y, Oshiro Y, Aogi K, Sagara Y, Ohi Y. Hida AI, et al. Among authors: baba s. Breast Cancer Res Treat. 2016 Jul;158(1):1-9. doi: 10.1007/s10549-016-3848-2. Epub 2016 Jun 3. Breast Cancer Res Treat. 2016. PMID: 27260189 Free PMC article.
Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study.
Zembutsu H, Nakamura S, Akashi-Tanaka S, Kuwayama T, Watanabe C, Takamaru T, Takei H, Ishikawa T, Miyahara K, Matsumoto H, Hasegawa Y, Kutomi G, Shima H, Satomi F, Okazaki M, Zaha H, Onomura M, Matsukata A, Sagara Y, Baba S, Yamada A, Shimada K, Shimizu D, Tsugawa K, Shimo A, Tan EY, Hartman M, Chan CW, Lee SC, Nakamura Y. Zembutsu H, et al. Among authors: baba s. Clin Cancer Res. 2017 Apr 15;23(8):2019-2026. doi: 10.1158/1078-0432.CCR-16-1779. Epub 2016 Oct 19. Clin Cancer Res. 2017. PMID: 27797974
Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.
Taira N, Sawaki M, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Ohashi Y, Mukai H, Kawahara T; RESPECT Study Group. Taira N, et al. Among authors: baba s. J Clin Oncol. 2021 Aug 1;39(22):2452-2462. doi: 10.1200/JCO.20.02751. Epub 2021 Apr 9. J Clin Oncol. 2021. PMID: 33835842
Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial.
Hagiwara Y, Sawaki M, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, Takahashi M, Saito T, Baba S, Kobayashi K, Mukai H, Taira N. Hagiwara Y, et al. Among authors: baba s. Breast Cancer Res Treat. 2021 Aug;188(3):675-683. doi: 10.1007/s10549-021-06253-0. Epub 2021 Jun 2. Breast Cancer Res Treat. 2021. PMID: 34080094 Clinical Trial.
Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial.
Takumoto Y, Shiroiwa T, Shimozuma K, Iwata H, Takahashi M, Baba S, Kobayashi K, Hagiwara Y, Kawahara T, Uemura Y, Mukai H, Taira N, Sawaki M. Takumoto Y, et al. Among authors: baba s. Clin Drug Investig. 2022 Mar;42(3):253-262. doi: 10.1007/s40261-022-01124-y. Epub 2022 Mar 1. Clin Drug Investig. 2022. PMID: 35233755 Free PMC article. Clinical Trial.
2,940 results